MO-I-500 is a pharmacological inhibitor of m6A demethylase FTO, inhibits purified FTO demethylase catalyzing demethylation with IC50 of 8.7 uM.
MO-I-500 treated cells exhibited a global increase in RNA methylation.
HeLa cells treated with 25 μM MO-I-500 for 24 hours showed a 9.3% increase in N6-methyl-adenosine content in total RNA.
MO-I-500 treatment caused a dramatic (>95%) inhibition in colony formation in SUM149-Luc cells.
MO-I-500 modulates various microRNA in treated (25uM) HeLa cells.
MO-I-500 treatment also led to decreased levels of FTO and IRX3 proteins in the SUM149 cells, with relatively little effect on cell growth.
MO-I-500 can strongly reduce the adverse effects of streptozotocin (STZ) model of AD in human astrocytoma CCF-STTG1 cells.
